Bioanalytical Assay Development, GLP Validation to ICH M10 by PhDs at 20+ Year, FDA-Inspected Lab

Bioanalytical assay development and qualification help determine the design implications, limitations, favorable conditions, and suitability of a drug for the intended treatment. Specifically, bioanalytical assays enable precise identification and quantitation of a compound in a biological matrix. Optimal assay development and validation involve numerous scientific and regulatory considerations, and several such methods help measure various aspects of a drug compound. We recommend understanding the analyte’s physicochemical properties ahead of starting assay development and validation. At NorthEast BioLab, we offer custom assay development and validation services for your proprietary or commercially available compound as per various regulatory guidance.

The primary intent of assay validation is to perform a regulated (GLP/GCP) study with reproducible and reliable results for sponsors. At NorthEast BioLab, we perform method validation to verify assay parameters such as precision, accuracy, selectivity, sensitivity, and stability throughout the bioanalytical testing process. We complete three/six independent validation runs over multiple days to estimate intra-day and inter-day accuracy and precision, as described in the assay validation FDA guideline white papers. All applicable experiments for reference standards and critical reagents, calibration curve, QCs, matrix effect, matrix suppression, extraction recovery, and carryover are covered as well. In-process stability experiments for bench-top, freeze-thaw cycles, and -70C stability in relevant matrices. Typically, a fully validated method is appropriate during preclinical and clinical development phases of the drug development process. NorthEast Biolab provides full assay method validation services according to FDA guidelines for both small and large molecules.

Robust bioanalytical assay development and validation are essential to accurate measurements of drugs, metabolites, and biomarkers in bioanalytical assays. Ahead of getting started, we do publication research to become familiar with drug compounds or biomarkers. For example, we must consider the nature and any relevant characteristics of the bioanalytical sample itself. Thus, the sample composition and expected concentration of the analyte constitute noteworthy criteria among several other factors. US FDA, ICH, and other regulatory agencies provide bioanalytical method development guidelines for setting up reliable bioanalytical assays. Generally, the key characteristics for the execution of an acceptable method are sensitivity selectivity, reproducibility, intra-day and inter-day precision and accuracy, dilutional integrity, matrix effects, and analyte stability under all sample storage, handling, and preparation conditions. Assay qualification demonstrates that an accepted method will provide meaningful data for the specific conditions, matrices, and samples intended for the procedure. Our veteran team of bioanalysis experts is equipped to handle full assay validation for small and large molecule according to FDA guidance.

For bioanalytical assays, the FDA, EMA, ICH, and other regulatory agencies provide biological assay development and validation guidelines outlining the required parameters for appropriate method validation and sample analysis. We evaluate parameters for sensitivity, selectivity, reproducibility, intra-day accuracy and precision, dilution integrity, matrix effect, and analyte recovery during bioanalytical testing. A full method validation study must be completed for any custom bioanalytical assay method that is new or developed based on the scientific publications. A fully validated method shows that it can determine the concentrations of analytes such as a drug, metabolite(s), or biomarkers reliably in a specific biological sample matrix from a particular species.

FDA has issued multiple guideline documents to inform the development and validation of bioanalytical assays used for nonclinical and clinical studies focused on pharmacokinetics, toxicokinetics, or biomarker data. FDA assay development guidelines apply to chromatographic assays (CCs) and ligand binding assays (LBAs) that quantitate the levels of drugs, metabolites, therapeutic proteins, and biomarkers in biological matrices such as blood, serum, plasma, urine, and a variety of tissues. Assay development and validation ensure that the data reliability by addressing certain key questions: Does the assay measure the intended analyte? What is the variability within these measurements? What range of measurements provides reliable data? How do sample collection, handling, and storage affect the data reliability for bioanalytical assay?

In assay validation there are specific parameters mentioned in bioanalytical assay validation FDA guidance. Typical method validation parameters to be considered are:

At NorthEast Bioanalytical Laboratories, we provide reproducible data for bioanalytical testing and assay validation service with full confidence to our client for regulatory submission.

Bioanalytical testing is a sub-discipline of analytical chemistry. It covers the quantitative measurement of xenobiotics (drugs and their metabolites, and biological molecules in various locations or concentrations) and biotics (macromolecules, proteins, DNA, RNA, large molecule drugs, metabolites) in biological systems. Bioanalytical method development is the quantitative determination of drugs and metabolites in biological matrices such as blood, serum, plasma, urine, tissue, and skin samples as applied to toxicology, pharmacology, bioequivalence, pharmacokinetics, and bioavailability studies in animals or humans. Immunogenicity tests are bioanalytical methods that target anti product antibodies in serum or plasma. Bioanalytical assay qualification is not intended to elucidate quality parameters (e.g., identity, purity) of a biotech product, instead bioanalytical analysis determines the quantity of a drug or the presence of induced antibodies in biological samples by using different bioanalytical techniques.

Bioanalytical assays focused on pharmacokinetics, bioavailability, toxicokinetics, immunogenicity, or biomarker testing play a crucial role in the discovery and development of drug products. We recommend understanding the physicochemical properties of the analyte before assay development and validation. Consequently, our bioanalytical techniques allow reproducible and reliable quantitation of analytes in various biological matrices, such as plasma, urine, blood, or serum. During bioanalytical testing, assay development helps determine the design implications, limitations, favorable conditions, and suitability of a drug for the intended treatment. Additionally, bioanalytical assay development gets considerably informed by protein binding and in vivo/in vitro metabolism along with essential aspects of prior DMPK/ADME work on the method. NorthEast Biolab offers comprehensive assay development services and assay validation services for your critical bioanalytical studies.

In vitro assay development is a key component in this process, allowing for the creation of assays that accurately mimic the biological environment in controlled laboratory settings. This approach helps ensure that the assay is well-suited for its intended purpose, providing reliable and reproducible data. Our in vitro assay development services are designed to meet the specific needs of your bioanalytical studies, ensuring compliance with regulatory standards and scientific rigor.

Custom development runs across small and large molecules: new chemical entities, peptides, oligonucleotides, monoclonal antibodies, antibody-drug conjugates, biosimilars, and cell and gene therapy analytes. Platform follows the analyte, LC-MS/MS and hybrid LC-MS, ELISA and MSD, qPCR and ddPCR, flow cytometry, with full validation to FDA and ICH M10 guidance where the study demands it.

Judge a provider on four things. Whether the method is built for your stage, so you are not billed GLP rigor for a discovery question. Whether validation follows FDA, ICH M10 and EMA guidance with the parameters documented, not asserted. Whether timelines are written down, scope and quote within two business days here, development in weeks not quarters. And whether the scientists who develop the method are the ones who answer when a sample looks odd, which is the quiet difference between a vendor and a partner.

Full validation is for a new method facing regulators. Partial validation covers a validated method that changed in one dimension, matrix, species, range, anticoagulant. Cross-validation proves two labs or two methods read the same truth, which is what a mid-study transfer or a two-lab program needs. The Method Validation page linked from this one walks the tiers; the practical answer is that we name the tier in writing before you commit, so you never buy more validation than the change requires.

It means the method is proven for its context of use rather than against the full GLP parameter set. For discovery screens, exploratory endpoints and internal decisions, fit-for-purpose is not a compromise, it is the correct tier, at a fraction of the cost and time. The moment data faces FDA, full validation takes over, and a method built here graduates with its development history intact rather than starting again.

Development typically runs two to four weeks. Full validation typically takes four to six weeks on ligand binding platforms and two to three weeks on LC-MS/MS, with a written scope back within two business days of your inquiry. Where a method transfers in rather than starts fresh, the calendar shortens further, which is one reason transfer beats de novo every time.